Used as a prodrug in cancer chemotherapy, particularly for colorectal and ovarian cancers. Its structure allows for improved stability and reduced side effects compared to active Pt(II) forms. The compound is designed to be activated under specific conditions in the tumor environment, such as in the presence of reducing agents like glutathione, which helps release the active oxaliplatin and enhance targeted cytotoxicity. This selective activation minimizes damage to healthy tissues and improves therapeutic efficacy. Also explored in combination with nanocarriers for targeted drug delivery systems to further increase tumor accumulation and reduce systemic toxicity.